… is the lack of reliable genetic markers predicting the clinical course … prostate tumors from
patients with distinct clinical outcomes after therapy as well as metastatic human prostate cancer …

… prostate cancer (mCRPC) has been well-defined, but the association of genomic findings
with patient clinical outcomes … profiles, histology, and clinical outcomes for 429 patients with …

… could improve survival of men with oligometastatic prostate cancer. Improved clinical
outcomes observed with local treatment of other primary cancers in the metastatic setting 66,67,68,…

… Clinically, small cell prostate cancer and NEPC are often manifested by the presence of
visceral or large soft tissue metastatic disease, a disproportionately low serum prostate-specific …

… clinical trials comparing the efficacy of aggressive therapies with that of more conservative
therapies for clinically localized prostate cancer… sociodemographic and clinical characteristics …

… In this Review, we describe the pathophysiology of prostate cancer bone metastases (PCBMs)
and the clinical burden of skeletal metastases in this setting. We review the clinical data …

… induction and progression of prostatic neoplasia and that … , determine the clinical outcome
of individual prostate cancers. … of prostate cancers,thus influencing appropriate clinical …

… of hormone-refractory prostate cancer using matched hormone-… to hormone-refractory
prostate cancer utilising 68 matched hormone … of prostate cancer to the hormone-refractory state. …

… to be a better predictor of aggressive prostate cancer than Ki67 alone. Finally, we show that
Gleason grading, which is often used to predict clinical outcome, was not a good predictor of …

… the outcome of a cohort of patients with prostate cancer treated by … , and overall survival as
clinical endpoints. By the following … outcome for patients with Gleason score 3+3=6 prostatic …